Perceptive Advisors LLC raised its stake in Quotient Ltd (NASDAQ:QTNT) by 61.9% during the fourth quarter, HoldingsChannel reports. The firm owned 6,033,020 shares of the company’s stock after purchasing an additional 2,306,034 shares during the quarter. Quotient accounts for about 1.0% of Perceptive Advisors LLC’s portfolio, making the stock its 25th largest position. Perceptive Advisors LLC owned about 0.13% of Quotient worth $29,683,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of QTNT. Teachers Advisors LLC acquired a new stake in Quotient in the 2nd quarter valued at about $345,000. TIAA CREF Investment Management LLC acquired a new stake in Quotient in the 2nd quarter valued at about $520,000. Nationwide Fund Advisors acquired a new stake in Quotient in the 2nd quarter valued at about $111,000. New York State Common Retirement Fund acquired a new stake in Quotient in the 2nd quarter valued at about $101,000. Finally, Northern Trust Corp acquired a new stake in Quotient in the 2nd quarter valued at about $1,783,000. 68.77% of the stock is currently owned by institutional investors.
Shares of Quotient Ltd (NASDAQ QTNT) opened at $5.47 on Monday. The company has a current ratio of 2.34, a quick ratio of 1.65 and a debt-to-equity ratio of 22.54. Quotient Ltd has a 12-month low of $2.78 and a 12-month high of $7.74.
In other Quotient news, Director Brian Mcdonough bought 10,000 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were acquired at an average price of $3.87 per share, with a total value of $38,700.00. Following the transaction, the director now owns 47,747 shares of the company’s stock, valued at $184,780.89. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Prondzynski Heino Von bought 12,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were acquired at an average cost of $4.28 per share, for a total transaction of $51,360.00. The disclosure for this purchase can be found here. 29.00% of the stock is currently owned by company insiders.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Ltd (NASDAQ:QTNT).
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.